Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Melanoma 13Multiple Myeloma 6Thyroid Neoplasms 5Lymphoma 5Hematologic Neoplasms 5Glioma 4Colorectal Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Thyroid Carcinoma, Anaplastic 3Prostatic Neoplasms 3Brain Neoplasms 3Thyroid Cancer, Papillary 2Pancreatic Neoplasms 2Neurofibromatosis 1 2Neoplasm Metastasis 2Lung Neoplasms 2Adenocarcinoma, Follicular 2Uveal Melanoma 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid cancer, follicular 1Thyroid cancer, Hurthle cell 1Stomach Neoplasms 1Solid Tumors, KRAS Mutation; SOS1 1Rectal Neoplasms 1Ovarian Neoplasms 1Neurofibroma, Plexiform 1Leukemia, Myelomonocytic, Juvenile 1Glioblastoma 1

Interventions

trametinib 1dabrafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Differentiated Thyroid Cancer (DTC) × trametinib × Clear all
NCT04940052 2026-06-04

Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer

Novartis

Phase 3 Active not recruiting
153 enrolled 15 charts
EndocrineHead & Neck

Differentiated Thyroid Cancer (DTC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡